Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: N06DX01

Axura(memantine hydrochloride)

Alzheimer Disease

Marketing Authorisation Holder: Merz Pharmaceuticals GmbH

EMA Authorisation: 17/05/2002

INN: memantine

Indication

Treatment of patients with moderate to severe Alzheimer's disease.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Axura — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.